LANIQUIDAR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C37H36N4O3
Molecular Weight	584.7067
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CCC5=CC=C(OCC6=CC=C7C=CC=CC7=N6)C=C5)CC4

InChI

InChIKey=TULGGJGJQXESOO-UHFFFAOYSA-N

InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3

HIDE SMILES / InChI

Molecular Formula	C37H36N4O3
Molecular Weight	584.7067
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10778964 | https://clinicaltrials.gov/ct2/show/NCT00028873

LANIQUIDAR is a P-glycoprotein inhibitor. It was used in trials studying the treatment of breast cancer.

Approval Year

PubMed

Title	Date	PubMed
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.	2000 Apr	10778964
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.	2000 Jul	10914699

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:39:19 GMT 2023` Edited by `admin` on `Fri Dec 15 16:39:19 GMT 2023`
Record UNII	K3FRN4DDOY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LANIQUIDAR

Official Name

English

Laniquidar [WHO-DD]

Common Name

English

METHYL 6,11-DIHYDRO-11-(1-(2-(4-(-2-QUINOLYLMETHOXY)PHENYL)ETHYL)-4-PIPERIDINYLIDENE)-5H-IMIDAZO(2,1-B)(3)BENZAZEPINE-3-CARBOXYLATE

Systematic Name

English

laniquidar [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1744